Foresite Capital Opportunity Fund V, L.P.
CIK 0001792205 Name as filed on the most recent filing
Filed as Foresite Capital Opportunity Fund V, L.P. (12)
21 transaction lines · from 12 filings · filed 2021-12-23 to 2026-08-10 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
- ISSUER Latigo Biotherapeutics, Inc. 1 filings
- ISSUER Eikon Therapeutics, Inc. 1 filings
- ISSUER Alumis Inc. 5 filings
- ISSUER Theseus Pharmaceuticals, Inc. 2 filings
- ISSUER Kinnate Biopharma Inc. 1 filings
- ISSUER Pardes Biosciences, Inc. 2 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-10 |
Latigo Biotherapeutics, Inc. LTGO |
P, Open-market purchase | 140,000 acquired | 18.00 | 2,520,000.00 | Form 4, filing 0001104659-26-093580 | |
| 2026-02-04 |
Eikon Therapeutics, Inc. EIKN |
P, Open-market purchase | 55,555 acquired | 18.00 | 999,990.00 | Form 4, filing 0001104659-26-011662 | |
| 2026-01-08 |
Alumis Inc. ALMS |
P, Open-market purchase | 294,117 acquired | 17.00 | 4,999,989.00 | Form 4, filing 0001104659-26-003017 | |
| 2026-01-08 |
Alumis Inc. ALMS |
P, Open-market purchase | 117,647 acquired | 17.00 | 1,999,999.00 | Form 4, filing 0001104659-26-003017 | |
| 2025-11-21 |
Alumis Inc. ALMS |
P, Open-market purchase | 72,212 acquired | 7.38 | 532,924.56 | Form 4, filing 0001104659-25-115951 | |
| 2025-11-19 |
Alumis Inc. ALMS |
P, Open-market purchase | 190,500 acquired | 6.56 | 1,249,680.00 | Form 4, filing 0001104659-25-114267 | |
| 2025-11-18 |
Alumis Inc. ALMS |
P, Open-market purchase | 117,374 acquired | 6.19 | 726,545.06 | Form 4, filing 0001104659-25-114267 | |
| 2025-11-17 |
Alumis Inc. ALMS |
P, Open-market purchase | 150,000 acquired | 5.59 | 838,500.00 | Form 4, filing 0001104659-25-114267 | |
| 2025-11-17 |
Alumis Inc. ALMS |
P, Open-market purchase | 50,000 acquired | 5.60 | 280,000.00 | Form 4, filing 0001104659-25-114267 | |
| 2025-05-06 |
Alumis Inc. ALMS |
P, Open-market purchase | 20,000 acquired | 4.34 | 86,800.00 | Form 4, filing 0001104659-25-045219 | |
| 2025-05-02 |
Alumis Inc. ALMS |
P, Open-market purchase | 25,000 acquired | 4.62 | 115,500.00 | Form 4, filing 0001104659-25-045219 | |
| 2024-07-01 |
Alumis Inc. ALMS |
P, Open-market purchase | 2,187,500 acquired | 16.00 | 35,000,000.00 | Form 4, filing 0001104659-24-077876 | |
| 2024-07-01 |
Alumis Inc. ALMS |
P, Open-market purchase | 312,500 acquired | 16.00 | 5,000,000.00 | Form 4, filing 0001104659-24-077876 | |
| 2023-07-17 |
Theseus Pharmaceuticals, Inc. THRX |
P, Open-market purchase | 523,450 acquired | 2.97 | 1,554,646.50 | Form 4, filing 0001209191-23-042720 | |
| 2023-07-17 |
Theseus Pharmaceuticals, Inc. THRX |
P, Open-market purchase | 176,550 acquired | 2.97 | 524,353.50 | Form 4, filing 0001209191-23-042720 | |
| 2023-05-08 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 1,550,956 acquired | 2.80 | 4,342,676.80 | Form 4, filing 0001209191-23-028527 | |
| 2023-05-08 |
Kinnate Biopharma Inc. KNTE |
P, Open-market purchase | 229,044 acquired | 2.80 | 641,323.20 | Form 4, filing 0001209191-23-028527 | |
| 2023-04-05 |
Pardes Biosciences, Inc. PRDS |
P, Open-market purchase | 773,952 acquired | 1.50 | 1,160,928.00 | Form 4, filing 0001213900-23-028117 | |
| 2022-12-29 |
Theseus Pharmaceuticals, Inc. THRX |
P, Open-market purchase | 250,000 acquired | 5.00 | 1,250,000.00 | Form 4, filing 0001209191-23-000204 | |
| 2022-12-29 |
Theseus Pharmaceuticals, Inc. THRX |
P, Open-market purchase | 250,000 acquired | 5.00 | 1,250,000.00 | Form 4, filing 0001209191-23-000204 | |
| 2021-12-22 |
Pardes Biosciences, Inc. PRDS |
P, Open-market purchase | 325,000 acquired | 10.00 | 3,250,000.00 | Form 4, filing 0001213900-21-067341 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Foresite Capital Opportunity Fund V, L.P., insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001792205
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6